Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The gross margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
0.00%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Greenwich LifeSciences, Inc.
Market Cap
$238.81M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$242.02M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$236.58M
Gross Margin
53.14%
TTM Avg
76.57%
3Y Avg
72.53%
5Y Avg
61.83%
Market Cap
$236.39M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
Market Cap
$242.50M
Gross Margin
N/A
TTM Avg
31.32%
3Y Avg
30.59%
5Y Avg
32.68%
Market Cap
$235.73M
Gross Margin
54.88%
TTM Avg
55.31%
3Y Avg
58.01%
5Y Avg
59.27%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | $238.81M | 0.00% | 0.00% | 0.00% | 0.00% |
| High Tide Inc. (HITI)vs › | $237.69M | 25.85% | 26.57% | 27.09% | 30.11% |
| Invivyd, Inc. (IVVD)vs › | $237.22M | 91.35% | 93.31% | 46.66% | 31.10% |
| Galectin Therapeutics Inc. (GALT)vs › | $242.02M | 0.00% | 0.00% | 0.00% | 0.00% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.58M | 53.14% | 76.57% | 72.53% | 61.83% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.39M | 79.48% | 71.93% | 74.52% | 72.98% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A | 31.32% | 30.59% | 32.68% |
| Q32 Bio Inc. (QTTB)vs › | $242.87M | 99.84% | 50.00% | 75.00% | 50.00% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.73M | 54.88% | 55.31% | 58.01% | 59.27% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $235.36M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
